异名 Sandostatin、SMS 201-995 化学名 D-苯丙酰-L-半胱氨酰-L-苯丙酰-D-色胺酰-L-赖氨酰-L-苏氨酰-L-半胱氨酰-L-苏氨醇环(2→7)二硫化物药效分类生长抑素类开发单位山道士公司实验室(瑞士) 上市厂商山道士公司,1988年于新西兰首次上市,并已在英、美、瑞士等国上市。药理本品与天然内源性生长抑素具有类似的作用,且作用较强而持久,如本品抑制生长激素的ID_(50)为每小时0.04μg/kg,较生长抑素(每小时1.7μg/kg)强45倍;抑制胰岛素的ID_(50)为每小时3.8μg/kg,较之强1.3 Synonyms Sandostatin, SMS 201-995 Chemical name D-phenylpropionyl-L-cysteinyl-L-phenylpropionyl-D-tryptophanyl-L-lysyl-L-threonyl-L- Cystinyl-L-threonine ring (2 → 7) Disulfide Pharmacodynamic Category Somatostatin Development Unit Hillsborough Laboratories (Switzerland) Listed manufacturer Hillsborough, first listed in New Zealand in 1988 and has In Britain, the United States, Switzerland and other countries listed. Pharmacology This product and the natural endogenous somatostatin has a similar role, and the role of strong and lasting, such as the product inhibiting growth hormone ID_ (50) 0.04μg / kg per hour, compared with somatostatin (1.7 μg / kg) was 45 times stronger than that of the control. The ID_ (50) of insulin inhibition was 3.8 μg / kg per hour,